Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.
AI: the Next Big Thing
In the past three months, investors have thrown over $27bn at US artificial intelligence (AI) start-ups, according to data from PitchBook. The Financial Times reported that AI “godmother” Fei-Fei Li has built a start-up called World Labs, valued at more than $1bn. Elsewhere, Anthropic is to collaborate with Menlo Ventures on a new $100m fund for AI start-ups; its chatbot, Claude, will recommend deals. Samsung [SSNLF] announced Thursday it is to buy British AI start-up Oxford Semantic Technologies.
Chip Politics: Winners and Losers
Taiwan Semiconductor Manufacturing Co [TSM] reported a 36% increase in net profit for Q2, driven by the ongoing AI boom. Nevertheless, a chip selloff continued on Thursday; Samsung dropped as much as 3.3% and Tokyo Electron [8035:T] by 11%. However, US-based firms such as Intel [INTC] and Globalfoundries [GFS] bucked the trend, closing up 8.2% and 14% Wednesday; Bloomberg reported that investors are increasingly turning from mega-caps to “underdog” chip stocks, such as Intel or AMD [AMD].
Nokia Still Stuck in 5G Doldrums
The share price of the Finnish giant [NOKIA:HE] fell 9% Thursday morning in Helsinki, after it reported Q2 sales were the lowest they’ve been since 2015. Weak investment in network upgrades remains a headwind for both Nokia and regional rival Ericsson [ERIC], Bloomberg reported. Shares in ABB Ltd. [ABB:ST] also fell, after the Swedish-Swiss robotics firm reported a decline in orders; weaker demand for its automation products undercut gains in its power grid arm.
Pharma Stocks Rise on J&J Earnings
Johnson & Johnson [JNJ] posted better-than-expected Q2 2024 earnings on Wednesday. “We have strong momentum with key end-market products and continue to advance our pipeline with significant clinical and regulatory milestones being attained,” said CEO Joe Wolk on the earnings call. With J&J widely considered a bellwether for the broader sector, other pharma stocks including Bristol-Myers Squibb [BMY] and AbbVie [ABBV] rose on the news. Meanwhile, Italy’s Angelini is weighing a merger with one of three US biotechs.
EV Sales Grow in Europe
Italian electric vehicle (EV) demand more than doubled in June following government subsidies. Second-hand EVs are now as affordable as petrol cars in the UK, according to data from Auto Trader reported by the Financial Times. Used EV sales were up 63% in H1. Elsewhere, Volvo [VLVCY] reported better-than-expected Q2 results Thursday but lowered its full-year retail sales forecast over EV tariffs; Renault [RNLSY], meanwhile, said its H1 sales volume rose 1.9% on strong demand for hybrids.
Disclaimer Past performance is not a reliable indicator of future results.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.
*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.
Continue reading for FREE
- Includes free newsletter updates, unsubscribe anytime. Privacy policy
